Abstract. Pancreatic cancer (PaC) is characterized by a highly inflammatory tumor microenvironment, and inflammatory mediators are implicated in the progression of this cancer. Regenerating gene protein (Reg) 3A is significantly upregulated during pancreatic inflammation, and has been demonstrated to serve an important role during PaC progression, based on its increased expression levels in PaC and potent cell proliferation-promoting activity. The aim of the present study was to investigate the effect of eckol, a phlorotannin compound with a variety of biological activities including anti-inflammatory, anti-tumor and cytoprotective effects, on Reg3A-induced proliferation of human SW1990 PaC cells. SW1990 cells were pre-treated with eckol for 48 h at concentrations of 5, 10 and 20 µg/ml. Subsequently, Reg3A protein was added to the culture media at a final concentration of 50 ng/ml in the presence or absence of eckol for 24 h. The cytotoxicity and proliferative capacity of the SW1990 cells was determined using an MTT and flow cytometry analysis. Cell colony formation was also used to determine the effect of eckol on the anchorage-independent growth and colony-forming capacity of Reg3A-treated PaC cells. The expression levels of cyclin D1, STAT3, JAK2, and NF-κB p65 were measured with reverse transcription-quantitative PCR and western blotting. Eckol reduced Reg3A-promoted cell survival, inhibited Reg3A-induced cell cycle progression and inhibited colony growth of SW1990 cells in soft agar in a concentration-dependent manner. Additionally, the Reg3A-mediated upregulation of expression of JAK2, STAT3,
Introduction
Pancreatic cancer (PaC), known as the king of carcinoma, is a type of highly lethal malignant tumor with high rate of incidence around the world (1). The 5-year relative survival rate of PaC is <8%, due to its rapid progression, asymptomatic development, poor prognosis and the relative lack of effects of treatment (2) . The etiology and pathogenesis of PaC still remains unclear. However, regenerating gene protein (Reg) 3A has been generally accepted to serve an important role during pancreatic carcinogenesis and PaC progression, based on its high expression in PaC and tumor-promoting activity (3) (4) (5) (6) . Reg proteins are members of the calcium-dependent C-type lectin family, which have been characterized as promoters of proliferation and differentiation in a range of cell types (7) . In humans, 5 Reg family proteins including Reg1A, Reg1B, Reg3A, Reg3G and Reg4 have been identified (4) . Among them, Reg3A is selectively expressed in the pancreas and small intestine (8) . During pancreatic infl ammation, Reg3A expres- (8) . During pancreatic infl ammation, Reg3A expres- (8) . During pancreatic inflammation, Reg3A expression is significantly increased and has thus also been named pancreatitis-associated protein (5, 6) . Elevated concentrations or expression of Reg3A in pancreatic juice/serum (9, 10) or tumor tissues (5, 6) have been reported in patients with PaC. Reg3A may promote the survival, proliferation, growth of PaC cells and acinar-to-ductal metaplasia formation, and overexpression of Reg3A in PaC is significantly associated with the aggressiveness of the tumor (5, 6) . Therefore, during pancreatic inflammation-mediated upregulation of Reg3A, Reg3A may function as an oncogene to promote the development and progression of PaC.
Although PaC therapies, including surgical resection, chemotherapy and radiotherapy have improved over a number of decades, the outcomes of patients with PaC have not improved significantly (11) . Therefore, there is an need urgent to develop alternative therapeutic approaches which may improve control of the aggressiveness of PaC. (11, 12) . Eckol, a phlorotannin component isolated from brown algae, is a marine natural product with a variety of potent biological activities (13) . For example, eckol has been demonstrated to exhibit antioxidant and cytoprotective properties (14) (15) (16) (17) , neuroprotective effect (18) (19) (20) and anti-adipogenic activities (21) . Additionally, eckol is also a well-known anti-inflammatory agent. Jung et al (22) demonstrated that eckol could inhibit lipopolysaccharide (LPS)-induced nitric oxide production in RAW264.7 macrophages in a dose-dependent manner. In HepG2 cells, eckol significantly inhibited LPS-stimulated inflammatory responses without any cytotoxicity (23) . A few previous studies have demonstrated the cytotoxic effects of eckol against tumors (24, 25) . As the source of eckol, brown algae has long been considered to exhibit relatively higher anti-tumor activities compared with other algae (24) . Hyun et al (25) reported that eckol treat- (25) reported that eckol treatment decreased the tumorigenic capacity of glioma cells, and sensitized these cell to established anticancer treatments, suggesting a novel potential adjuvant capacity of eckol for treating patients with cancer. However, the effect of eckol on PaC has not been investigated, to the best of our knowledge.
Based on the role of pancreatic inflammation-upregulated Reg3A in PaC progression, together with the existing evidence that eckol has potential anti-inflammatory and anti-tumor effects, eckol may inhibit Reg3A-induced proliferation of PaC cells, and thus protect against progression of inflammation-associated PaC. To test this hypothesis, the effect of eckol on the proliferation of Reg3A-stimulated human SW1990 PaC cells was determined. Human pancreatic adenocarcinoma cell line SW-1990 is a representative and common PaC cell line with aggressive behaviors (5, 6) . A previous study studied the effect of Reg3A on the proliferation of five different PaC cell lines; AsPC-1, Mia Paca-2, BxPC-3, SW1990, PANC-1 (6). The results showed that the proliferation-promoting effect of Reg3A was most marked in the SW1990 cells, that is, SW1990 was the most sensitive cell line to exogenous Reg3A stimulation amongst the studied cell lines. The aim of the present study was to determine whether eckol may potentially limit the malignant development of PaC driven by pancreatic inflammatory mediators such as Reg3A, a pancreatic inflammation-upregulated protein with pro-growth function.
Materials and methods
Cell culture and treatment. The human PaC cell line, SW1990 was obtained from American Type Culture Collection (American Type Culture Collection) was cultured in 5% CO 2 atmosphere at 37˚C in RPMI 1640 (Hyclone; GE Healthcare Life Sciences) supplemented with 10% fetal calf serum and 100 units/ml penicillin/streptomycin (both Invitrogen; Thermo Fisher Scientific, Inc.). SW1990 cells were pre-treated with eckol (Rongbao Environmental Technology Co., Ltd) for 48 h with 5, 10 and 20 µg/ml. Subsequently, Reg3A protein (Sino Biological Inc.) was added to the culture media at a final concentration of 50 ng/ml in the presence or absence of eckol for 24 h. The control cells were treated with the same volume of vehicle (DMSO).
Cytotoxicity assay. The cytotoxic effects of eckol on SW1990 cells was determined using an MTT assay as described previously (26) . Briefly, 4x10 3 SW1990 cells were plated per well in a 96 well microplates and pre-incubated for 24 h. Subsequently, the cells were treated with Reg3A and/or eckol as described above, after which 20 µl 5 mg/ml MTT (Sigma-Aldrich; Merck KGaA) was added to each well and the plates were incubated at 37˚C for a further 4 h. The survival rate of SW1990 cells was calculated as the A570 of treated cells/A570 of control cells. There were a total of 8 wells per condition.
Cell cycle assay. Following treatment with Reg3A and/or eckol, the SW1990 cells were stained with propidium iodide (PI; Sigma-Aldrich; Merck KGaA) at 4˚C for 30 min, and immediately analyzed using a Flow Cytometer and CellQuest Pro software version 5.1 (both BD Biosciences).
Colony formation in soft agarose. Following treatment with
Reg3A and/or eckol, the SW1990 cells were seeded in 6-well plates at a density of 500 cells per well with five replicates, and incubated for 2 weeks for the colony formation assay in soft agarose culture as described previously (5,6). RPMI 1640 medium (X2 concentration) was mixed with an equal volume of 1.2% melted agarose (Invitrogen; Thermo Fisher Scientific, Inc.) to prepare the agar. The number of colonies formed per 100 seeded SW1990 cells was assessed by counting under a compound light microscope at a magnification of x100.
Reverse transcription-quantitative (RT-q)PCR.
Total RNA was isolated from the cells using TRIzol ® Reagent (Invitrogen; Thermo Fisher Scientific, Inc.). The mRNAs were reverse-transcribed to cDNAs using a PrimeScript ® RT Master mix (Perfect Real Time; Takara Bio, Inc.) under the reaction conditions of 37˚C for 15 min and 85˚C for 5 sec. RT-qPCR was performed using an Applied Biosystems StepOnePlus™ system using a SYBR Green Premix kit (Takara Bio Inc.) as the fluorophore. Primers were as follows: Cyclin D1 forward, 5'-TCT ACA CCG ACA ACT CCA TCC G-3' and reverse, 5'-TCT GGC ATT TTG GAG AGG AAG TG-3'; STAT3 forward, 5'-CCC ATC CAG GCT GAG TAT GT-3' and reverse, 5'-GAT CCA GTC CGT GGA ACC AT-3'; JAK2 forward, 5'-CCT TGT ACT TCA CGA TGT TGT C-3' and reverse, 5'-GTG GAG ATG TGC CGC TAT G-3'; NF-κB p65 forward, 5'-CTT CAG AAT GGC AGA AGA TGA-3' and reverse, 5'-CAC ATA CAT AAC GGA AAC GAA A-3'; β-actin forward, 5'-TCA CCC ACA CTG TGC CCA TCT ACG A-3' and reverse, 5'-CAG CGG AAC CGC TCA TTG CCA ATG G-3'. The thermocycling conditions were: i) 95˚C For 10 min; and ii) 40 cycles of 95˚C for 30 sec, 58˚C for 30 sec and 72˚C for 30 sec. The mRNA levels of cyclin D1, STAT3, JAK2, and NF-κB p65 were normalized to those of β-actin. The results were analyzed using the 2 -∆∆Cq method (27) .
Western blotting. The protein expression levels of Cyclin D1, STAT3, JAK2 and NF-κB p65 were detected by western blotting. The total protein in the SW1990 cells was extracted using RIPA lysis and extraction buffer containing protease inhibitor cocktail (Pierce; Thermo Fisher Scientific, Inc. Statistical analysis. The statistical analyses were performed using SPSS version 12.0 (SPSS, Inc., Chicago, IL, USA). Data are expressed as the mean ± standard deviation of at least five repeats. The statistical significance of difference between groups was determined using a one-way ANOVA followed by a post-hoc Tukey's test. P<0.05 was considered to indicate a statistically significant difference. 
Results

Eckol decreases
JAK/STAT3 and NF-κB/cyclin D1 pathways may contribute to the protective effect of eckol on Reg3A-induced over-proliferation of SW1990 PaC cells.
Based on the above results, the possible underlying molecular mechanism involved in the protective effects of eckol on Reg3A-induced over-proliferation of SW1990 PaC cells were determined using RT-qPCR and western blot analysis of Reg3A signaling-associated molecules, including JAK2, STAT3, NF-κB and cyclin D1. As shown in 
Discussion
The association between inflammation and cancer is well-known and researched (28) . Inflammation is considered a hallmark and a dominant feature of cancer (28) . Evidence has shown that almost all tumors possess an inflammatory tumor microenvironment (28) . In PaC, there is an indispensable contribution of pre-existing inflammation to pancreatic carcinogenesis, which frequently manifests as a chronic inflammatory response to pancreatic diseases such as chronic pancreatitis, hereditary pancreatitis, and is a contributing risk factors in patients with PaC (29) . Furthermore, PaC is characterized by a highly inflammatory tumor microenvironment, and inflammatory mediators are implicated in the progression of this tumor (30) . Sustained inflammation within PaC tissues aggravates the behavior of cancer cells (such as cell proliferation and survival), affects the tumor microenvironment, and is conducive to the invasive growth of PaC (29, 31) . During the progression of PaC, additional inflammatory cells are recruited into the cancer microenvironment and the interaction between cancer-associated inflammation and tumor cells promotes the malignant progression of PaC (32) .
The molecular events involved in inflammation-associated cancer have been gradually uncovered (3-6,28-31). IL-6 has long been demonstrated as a well-known mediator involved in inflammation-associated pancreatic carcinogenesis (5,6). There is a synergistic effect of Reg3A and IL-6 on PaC development (5) . As a mediator induced by pancreatic infl am- (5) . As a mediator induced by pancreatic infl am-(5). As a mediator induced by pancreatic inflammation and a promoter of cancer cell growth in PaC, Reg3A serves an important role in the progression of PaC accompanied by pancreatic inflammation (3) (4) (5) (6) . Reg3A has been demonstrated to be overexpressed in 79% (30 out of 38) of pancreatic tissues from individuals with PaC (10). In a cohort of 36 patients who underwent resection for PaC (6), Reg3A mRNA expression levels in tumor tissues were significantly higher in the patients with inflammation history, in tumors >3 cm, in relatively undifferentiated tumors and in patients in Tumor-Node-Metastasis stage III-IV, indicating the association between the inflammatory mediator Reg3A and PaC malignancy.
In line with previous studies (5,6), 50 ng/ml exogenous Reg3A promoted cell growth, proliferation and tumor formation in human SW1990 PaC cells. In the present study, despite the fact that cell viability as assessed by MTT assay was not significantly influenced by eckol, there was a reduction in Reg3A-induced cell survival, the proportion of cells in the G2/M and S phases and the colony-forming ability of cells in eckol-treated SW1990 cells. The protective role of eckol in normal tissue cells has been well documented (25) . Eckol was previously found to exhibit cytoprotective activity in hepatocytes (17) , neurocytes (18, 19) , keratinocytes (33) and lung fibroblast cells (34) . In addition, eckol showed hepatoprotective activity in tacrine-treated in HepG2 cells (15) . Hyun et al (25) reported that treatment of glioma cells cultured in sphere forming condition, induced with epidermal growth factor and basic fibroblast growth factor, with 50 µM eckol significantly decreased cell proliferation and the formation of spheres and there was no significant increase in cell death when treated with 10-80 µM eckol. These previous studies suggest that eckol appears to exert dual regulatory effects on cell proliferation and viability. In the present study, eckol treatment inhibited the Reg3A-induced increase in proliferation without decreasing the viability of SW1990 cells. Therefore, eckol may be a safe compound for controlling the progression of PaC accompanied by pancreatic inflammation, which possesses activity against inflammation-driven PaC malignancies without significantly affecting the cell viability. The JAK2/STAT3 signal transduction pathway is closely associated with Reg3A-mediated PaC cell growth (5, 6) . The JAK2/STAT3 signaling pathway is an important pathway in a wide variety of malignant diseases including PaC (35) and is required for expression of Reg3A in response to the stimulation of proinflammatory factors (such as IL-6) (4,6). In the present study it was demonstrated that, Reg3A regulated the activation of JAK2 and STAT3, which is in agreement with Wang et al (6) and Liu et al (5) . Therefore, there may be crosstalk between Reg3A and JAK2/STAT3 signaling, forming a positive feedback loop, ultimately promoting PaC development (5) . In addition, STAT3 co-operates with NF-κB, another key molecule associated with malignant conversion and progression (36) by promoting cell prolifera-(36) by promoting cell prolifera-(36) by promoting cell proliferation, transformation and tumor development (37) . Cyclin D1 is one of important transcriptional targets of NF-κB which contributes to cell cycle progression (38) . Acceleration of the G1/S transition via regulation of the cell-cycle-associated protein cyclin D1 represents a key mechanism by which NF-κB promotes cell proliferation and functions as a cancer promoter (38) . Previous studies found that NF-κB and its gene product cyclin D1 are also involved in the proliferation-promoting effect of Reg3A on PaC cells (5, 6) . Therefore, Reg3A upregulates the NF-κB/cyclin D1 signaling pathway and interacts with the JAK2/STAT3 pathway to create a positive feedback loop to promote PaC development and progression. Treatment with eckol resulted in a significant suppression of Reg3A-upregulated the expression of JAK2, STAT3, NF-κB and cyclin D1 in SW1990 PaC cells. We thereand cyclin D1 in SW1990 PaC cells. We therefore hypothesized that eckol may exert its protective activity against Reg3A-incduced SW1990 cell proliferation, at least partly, by inhibition of JAK/STAT3 and NF-κB/cyclin D1 signaling pathways. In summary, in the SW1990 PaC cells, eckol exerted a protective effect on PaC cells from Reg3A-induced proliferation in a concentration-dependent manner, which was observed by the reduction of Reg3A-promoted cell survival and attenuation of Reg3A-induced cell cycle progression in the Reg3A-stimulated cells co-treated with eckol. In addition, colony growth of SW1990 PaC cells in soft agar was significantly increased in the presence of exogenous Reg3A, which was reversed by the addition of eckol and the expression levels of JAK2, STAT3, NF-κB and cyclin D1 were upregulated following treatment with Reg3A, and these were reversed when co-treated with eckol. Therefore, the Reg3A associated JAK/STAT3 and NF-κB/cyclin D1 signaling pathways may be involved in the protective effect of eckol on Reg3A-induced proliferation of SW1990 PaC cells. As Reg3A is as a protein upregulated during pancreatic inflammation with pro-growth functions, it serves an important role during inflammation-driven PaC malignancies, and the above results support the notion that eckol may be used as a potential protective agent against progression of PaC accompanied by pancreatic inflammation. However, the protective effects of eckol on the proliferation of PaC cells induced by other pro-proliferative factors other than Reg3A still require further study, to determine whether eckol effects are limited to the activity of Reg3A or not.
